• Skip to main content

Plain Language Summaries

Standalone, citable summaries published in the Future Science Group journals written to be understood by a lay audience

  • How To Publish
  • How to Write Plain Language Summaries
  • Frequently Asked Questions
  • Publications
    • Animated Videos
    • Bladder, Kidney and Genitals
    • Brain and Nerves
    • Cancer
    • Heart and Circulation
    • Infections
    • Muscle and Bone
    • Rare Diseases
    • Skin
    • Vaccines
  • Advisory Panel
  • Supporters
  • Blog
  • About Us
  • Contact Us

Rare Diseases


  • Prednisone and deflazacort in Duchenne muscular dystrophy: a patient perspective and plain language summary publication of the Cincinnati study

    Prednisone and deflazacort in Duchenne muscular dystrophy: a patient perspective and plain language summary publication of the Cincinnati study

    This plain language summary of publication, co-authored by a patient, a caregiver and a treating physician, includes the patient perspective and help patients with Duchenne muscular dystrophy and their caregivers understand the results of the Cincinnati study.

  • Plain language summary of the MPOWERED trial comparing the effectiveness, safety, and patient experiences’ of monthly injections and oral medication used to treat acromegaly

    Plain language summary of the MPOWERED trial comparing the effectiveness, safety, and patient experiences’ of monthly injections and oral medication used to treat acromegaly

    The MPOWERED study looked oral octreotide as a treatment for patients with acromegaly. This plain language summary can help people understand the findings from this study.

  • Plain language summary of the long-term effect of ataluren in patients with Duchenne muscular dystrophy

    Plain language summary of the long-term effect of ataluren in patients with Duchenne muscular dystrophy

    Read the latest plain language summary looking at how ataluren treatment in combination with standard of care can delay important signs of disease progression in patients with Duchenne muscular dystrophy.

  • Vosoritide treatment accelerates bone growth in children with achondroplasia

    Vosoritide treatment accelerates bone growth in children with achondroplasia

    Read the article summarising the results of two studies looking at vosoritide as a potential treatment for children with achondroplasia.

  • ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT)

    ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT)

    The first of it’s kind published in a peer-reviewed journal, this article published in Future Oncology provides a lay language summary of the ENLIVEN study.

Copyright © 2022 · Plain Language Summaries · Terms and Conditions · Privacy Policy ·